Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezetimibe + rosuvastatin (Hanmi Pharmaceutical)
- Development stage
- Phase 4
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ruvan-Z is a fixed-dose combination of rosuvastatin, an HMG-CoA reductase inhibitor (statin), and ezetimibe, a selective cholesterol absorption inhibitor. Rosuvastatin works by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the liver, thereby reducing endogenous cholesterol synthesis and upregulating hepatic LDL receptors to increase LDL clearance. Ezetimibe targets the Niemann-Pick C1-like 1 (NPC1L1) transporter in the small intestine, blocking the absorption of dietary and biliary cholesterol. Together, these complementary mechanisms provide a synergistic lipid-lowering effect, significantly reducing low-density lipoprotein cholesterol (LDL-C) levels. Ruvan-Z is developed and manufactured by Aristopharma in Bangladesh and is indicated as an adjunct to diet for the treatment of primary hyperlipidemia and homozygous familial hypercholesterolemia.
- Brand names
- Ruvan-Z
- Other names
- ezetimibe + rosuvastatin calciumezetimibe + rosuvastatin zincezetimibe/rosuvastatinrosuvastatin calcium + ezetimiberosuvastatin calcium/ezetimiberosuvastatin zinc + ezetimiberosuvastatin zinc/ezetimiberosuvastatin/ezetimibe
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on ezetimibe + rosuvastatin (Hanmi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezetimibe + rosuvastatin (Hanmi Pharmaceutical).